Saturday 17 October 2026 Export HRMY’s income statement to Excel — free account

Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024. In the quarter to June 2026, revenue grew 30.3%, EPS grew 88.4%, free cash flow grew 16.5% and total debt fell 10.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.

38.20 0.07 −0.18%

Follow HRMY

Alert me

Market cap: $2.2B
P/E: 12.2×
Fwd P/E: 9.4×
Dividend yield: —
F-score: 5/9
Altman Z: 5.23
Beneish M: −2.99
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 5.95

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	2	2	—	—	—	—	—	—	—	2	—

Insider Ownership 13.35%

Capital & Financial Ratios $m

Market Cap 2,230.00

Revenue 959.90

Net Income 181.27

Free Cash Flow 355.08

Net Debt (513.83)

Current Ratio 3.48

Debt/Equity 0.15

P/E ratio 12.20

Fwd P/E 9.39

P/S ratio 2.31

P/B ratio 2.21

Past 5Y EPS Growth —

This Y EPS Growth 45.81%

Next Y EPS Growth 12.37%

Next Y revenue growth 18.72%

Next 5Y EPS Growth 22.07%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 30.13%

10-year low 10-year high

P/S against its own 10 years 12.44%

10-year low 10-year high

P/B against its own 10 years 9.74%

10-year low 10-year high

EV/Sales against its own 10 years 12.99%

10-year low 10-year high

EV/FCF against its own 10 years 15.28%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	353	467	775	668
Receivables	74	83	97	111
Inventory	5	7	5	6
Other	6	8	14	10
	451	579	907	814

	2023	2024	2025	Q'26
Payables	18	14	18	22
ST’ Debt	15	16	20	20
Other	8	6	5	11
	164	175	252	234

Compound Annual Growth %

	10y	5y	3y
Sales	—	40.30%	25.64%
Cash Flow	—	0.00%	34.08%
Earnings	—	0.00%	(4.37%)
Book Value	—	55.03%	29.27%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	215	261	—	—	—
’25	185	200	239	244	868
’24	155	173	186	201	715
’23	119	134	160	168	582
’22	85	107	117	128	438
’21	60	74	81	91	305
’20	20	38	46	56	160

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	28	92	—	—	—
’25	34	79	109	126	348
’24	31	43	71	76	220
’23	43	37	63	77	219
’22	29	34	55	27	144
’21	13	18	30	38	99
’20	(27)	5	9	10	(3)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	28	92	—	—	—
’25	34	79	109	126	348
’24	31	42	70	75	219
’23	43	37	63	77	219
’22	(11)	34	55	27	104
’21	(87)	18	30	38	(2)
’20	(27)	5	9	8	(5)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.55	1.28	—	—	—
’25	0.78	0.68	0.87	0.38	2.71
’24	0.67	0.20	0.79	0.85	2.51
’23	0.48	0.56	0.63	0.45	2.13
’22	0.35	0.39	1.44	0.79	2.97
’21	0.13	0.24	(0.17)	0.38	0.58
’20	(4.96)	0.00	(0.14)	0.00	(2.48)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	28.97	25.09	31.54	18.61	28.14	25.52	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	52.74	45.20	62.09	55.60	41.61	40.93
People
People	Employees	—	—	—	150	150	180	200	246	268	293
	Revenue/emp, $m	—	—	—	0.04	1.06	1.70	2.19	2.37	2.67	2.96
Income, $m
Income, $m	Revenue	—	—	—	6	160	305	438	582	715	868
	Gross margin, %	—	—	0.00	73.69	82.64	81.82	80.93	79.17	78.06	77.16
	EBT	—	—	(40)	(152)	(37)	37	105	173	192	215
	EBT margin, %	—	—	0.00	(2,535.06)	(23.13)	12.25	23.91	29.79	26.84	24.76
	Net income	—	0	(40)	(152)	(37)	35	181	129	145	159
	Depreciation	—	—	0	4	13	21	25	24	23	24
Per share, $
Per share, $	Revenue	—	—	0.00	0.77	6.20	5.31	7.40	9.79	12.56	15.11
	Earnings	—	—	(1.10)	(19.54)	(2.48)	0.60	3.07	2.17	2.56	2.76
	Cash flow	—	—	(0.61)	(9.70)	(0.12)	1.71	2.44	3.69	3.86	6.06
	Capex	—	—	0.00	(16.35)	(0.08)	(1.74)	(0.68)	(0.01)	(0.02)	(0.01)
	Free cash flow	—	—	(0.61)	(26.05)	(0.19)	(0.03)	1.76	3.68	3.84	6.05
	Book value	—	—	(3.81)	(1.49)	3.77	3.24	6.81	7.85	11.59	15.14
	Shares, m	—	—	64	8	26	58	59	59	57	57
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	71.07	17.31	14.25	13.44	13.61
	P/S	—	—	—	0.00	5.83	8.03	7.16	3.15	2.74	2.48
	P/B	—	—	—	0.00	9.59	13.15	7.78	3.92	2.97	2.47
	EV/Sales	—	—	—	0.00	5.62	7.89	6.86	2.87	2.34	1.77
	EV/FCF	—	—	—	(8.62)	(296.82)	(1,384.74)	28.79	9.33	9.34	5.00
Cash, $m
Cash, $m	Operating cash flow	—	—	(39)	(75)	(3)	99	144	219	220	348
	Capex	—	—	(1)	(127)	(2)	(100)	(40)	0	(1)	0
	Free cash flow	—	—	(39)	(203)	(5)	(2)	104	219	219	348
Balance, $m
Balance, $m	Working capital	—	—	79	12	128	231	321	287	404	655
	Total debt	—	—	324	98	194	192	192	194	179	164
	Net debt	—	—	241	73	(34)	(42)	(131)	(160)	(288)	(612)
	Shareholders’ equity	—	—	(243)	(12)	97	187	403	467	659	870
Returns, %
Returns, %	ROA	—	—	(156.99)	(191.04)	(23.92)	8.04	32.78	17.35	16.07	13.98
	ROIC	—	—	0.00	(147.31)	16.91	37.94	27.68	39.08	32.13	50.40
	ROE	—	—	21.06	56.26	39.21	24.39	61.58	29.63	25.84	20.75

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SLS SELLAS Life Sciences Group, Inc.	$2.3B	— (loss-making)	— (loss-making)	−57.10% (below 0%: shrinking)	n/m	−3.52% (below 0%: shrinking)	0.00%	0.00%	Compare
CLDX Celldex Therapeutics, Inc.	$2.3B	— (loss-making)	— (loss-making)	−96.83% (below 0%: shrinking)	n/m	−35.45% (below 0%: shrinking)	100.00%	(366,468.18%)	Compare
HRMY Harmony Biosciences Holdings, Inc.	$2.2B	12.2×	9.4×	+30.32% (above 0%: growing)	+88.41% (above 0%: growing)	+16.53% (above 0%: growing)	75.81%	34.18%
AUPH Aurinia Pharmaceuticals Inc	$2.2B	6.9×	16.5×	+18.87% (above 0%: growing)	+81.25% (above 0%: growing)	+19.08% (above 0%: growing)	92.12%	48.19%	Compare
RXRX Recursion Pharmaceuticals, Inc.	$2.2B	— (loss-making)	— (loss-making)	−60.10% (below 0%: shrinking)	n/m	−32.03% (below 0%: shrinking)	(49.82%)	(1,759.69%)	Compare
VRDN Viridian Therapeutics, Inc.	$2.2B	— (loss-making)	— (loss-making)	+278.67% (above 0%: growing)	n/m	−41.39% (below 0%: shrinking)	100.00%	(44,460.56%)	Compare
IRON Disc Medicine, Inc.	$2.2B	— (loss-making)	—	—	n/m	+7.83% (above 0%: growing)	0.00%	0.00%	Compare
FTRE Fortrea Holdings Inc.	$2.2B	— (loss-making)	— (loss-making)	−4.52% (below 0%: shrinking)	n/m	+53.15% (above 0%: growing)	20.52%	2.18%	Compare
NVAX Novavax, Inc.	$2.1B	— (loss-making)	— (loss-making)	−76.30% (below 0%: shrinking)	n/m	+42.95% (above 0%: growing)	74.87%	(96.84%)	Compare
Median of peers	$2.2B	—	—	−57.10%	—	+2.15%	47.70%	(48.42%)

All 614 Biotechnology stocks →

Harmony Biosciences Holdings, Inc. (HRMY) key facts

Strength: Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
Harmony Biosciences Holdings, Inc. (HRMY) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, HRMY traded at $38.20, a market capitalization of $2.2 billion.
Return on equity was 20.8% and debt-to-equity 0.15.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 5.23 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.